|Application ||WB, E|
|Other Accession||Q8C735, Q4R8N2, Q5RHQ8, NP_775106.2|
|Predicted||Zebrafish, Monkey, Mouse|
|Calculated MW||61946 Da|
|Antigen Region||132-160 aa|
|Other Names||Protein lin-9 homolog, HuLin-9, hLin-9, Beta subunit-associated regulator of apoptosis, TUDOR gene similar protein, Type I interferon receptor beta chain-associated protein, pRB-associated protein, LIN9, BARA, TGS|
|Target/Specificity||This LIN9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 132-160 amino acids from the N-terminal region of human LIN9.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||LIN9 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a tumor suppressor. Inhibits DNA synthesis. Its ability to inhibit oncogenic transformation is mediated through its association with RB1. Plays a role in the expression of genes required for the G1/S transition.|
|Cellular Location||Nucleus, nucleoplasm Note=Found in perinucleolar structures. Associated with chromatin|
|Tissue Location||Expressed in thymus and testis.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LIN9 acts as a tumor suppressor. Inhibits DNA synthesis. Its ability to inhibit oncogenic transformation is mediated through its association with RB1. Plays a role in the expression of genes required for the G1/S transition.
Rose, J. Phd, et al. Mol. Med. (2010) In press :
Arking, D.E., et al. PLoS ONE 5 (3), E9879 (2010) :
Pilkinton, M., et al. Oncogene 26(54):7535-7543(2007)
Osterloh, L., et al. EMBO J. 26(1):144-157(2007)
Pilkinton, M., et al. J. Biol. Chem. 282(1):168-175(2007)
If you have any additional inquiries please email technical services at email@example.com.